We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
Pfizer (PFE - Free Report) closed at $40.64 in the latest trading session, marking a -0.76% move from the prior day. This change lagged the S&P 500's daily gain of 0.85%. Elsewhere, the Dow gained 0.75%, while the tech-heavy Nasdaq added 1.29%.
Prior to today's trading, shares of the drugmaker had lost 4.43% over the past month. This has lagged the Medical sector's gain of 9.03% and the S&P 500's gain of 12.44% in that time.
PFE will be looking to display strength as it nears its next earnings release, which is expected to be January 29, 2019. In that report, analysts expect PFE to post earnings of $0.63 per share. This would mark year-over-year growth of 1.61%. Meanwhile, our latest consensus estimate is calling for revenue of $13.77 billion, up 0.48% from the prior-year quarter.
Any recent changes to analyst estimates for PFE should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 2.63% lower within the past month. PFE is holding a Zacks Rank of #4 (Sell) right now.
In terms of valuation, PFE is currently trading at a Forward P/E ratio of 13.72. For comparison, its industry has an average Forward P/E of 14.21, which means PFE is trading at a discount to the group.
Also, we should mention that PFE has a PEG ratio of 2.04. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.92 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 93, which puts it in the top 37% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer (PFE) Stock Sinks As Market Gains: What You Should Know
Pfizer (PFE - Free Report) closed at $40.64 in the latest trading session, marking a -0.76% move from the prior day. This change lagged the S&P 500's daily gain of 0.85%. Elsewhere, the Dow gained 0.75%, while the tech-heavy Nasdaq added 1.29%.
Prior to today's trading, shares of the drugmaker had lost 4.43% over the past month. This has lagged the Medical sector's gain of 9.03% and the S&P 500's gain of 12.44% in that time.
PFE will be looking to display strength as it nears its next earnings release, which is expected to be January 29, 2019. In that report, analysts expect PFE to post earnings of $0.63 per share. This would mark year-over-year growth of 1.61%. Meanwhile, our latest consensus estimate is calling for revenue of $13.77 billion, up 0.48% from the prior-year quarter.
Any recent changes to analyst estimates for PFE should also be noted by investors. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 2.63% lower within the past month. PFE is holding a Zacks Rank of #4 (Sell) right now.
In terms of valuation, PFE is currently trading at a Forward P/E ratio of 13.72. For comparison, its industry has an average Forward P/E of 14.21, which means PFE is trading at a discount to the group.
Also, we should mention that PFE has a PEG ratio of 2.04. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 1.92 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 93, which puts it in the top 37% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks. Com to follow all of these stock-moving metrics, and more, in the coming trading sessions.